European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Post-Authorisation Safety Studies (PASS)

Slides:

Advertisements

Similar presentations

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)

Advertisements

Safety Reporting IN Clinical Trials

© Safeguarding public health Expert Group on Innovation in the Regulation of Healthcare products Adaptive Licencing workshop at the Wellcome Trust October.

„Ensuring Regulatory and Pharmacovigilance Compliance“ „Ensuring Regulatory and Pharmacovigilance Compliance“

Disclaimer The presentation is intended for educational purposes only and does not replace independent professional judgement. Statements of fact and opinions.

RMP: DEFINITIONS AND REGULATORY ASPECTS Marc Czarka, MD, FBCPM Managing Partner HM3A ( Market Autorisation and Access Associates )

Pharmacovigilance Dr. Muiris Dowling,

„Ensuring Regulatory and Pharmacovigilance Compliance“ „Ensuring Regulatory and Pharmacovigilance Compliance“

© Safeguarding public health Innovation; issues for regulators, society and industry. Overview of Conference topics Alasdair Breckenridge Medicines and.

Presentation based on Turner, J.R., New Drug Development, and Turner, J.R., Drug Cardiac Safety. Copyright © 2007, 2008 respectively, John Wiley & Sons,

Stefan Franzén Introduction to clinical trials.

Knowledge Update Clinical documentation: from preclinical studies to drug registration Split, 12 September 2008.

Reconstruction of the Pharmacovigilance System

GIQAR Annual Congress 25 – 26 th May Pv QA: Quality Assurance for Pharmacovigilance Allison Jack Manager, R&D Oversight – GCP/PV, Pfizer Ltd BARQA.

An agency of the European Union The older patient. Can the EMA assist in determining cost-effectiveness of treatments? Presented by: Francesca Cerreta.

Safety data collected during clinical trials is incorporated into the product’s approved label. Regulatory reviewers monitor products’ safety profiles.

Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.

Geriatric Medicines Strategy - Informal PhVWP Oct EMA Geriatric Medicines Strategy: focus on Pharmacovigilance Francesca Cerreta EMA, H-SE-CNS.

„Ensuring Regulatory and Pharmacovigilance Compliance“ „Ensuring Regulatory and Pharmacovigilance Compliance“

Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.

A S Nanivadekar Introduction to GCP. A S Nanivadekar Outline Definition and scope Definition and scope Purpose of clinical research Purpose of clinical.

Stefan Franzén Introduction to clinical trials.

H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.

Post marketing surveillance Claudio Ceconi ALL ABOUT CLINICAL TRIALS Rome, 29th & 30th May 2015.

PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.

Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.

1 10 th Annual European Scientific and Regulatory Affairs Conference New Pharmaceutical legislation: One year experience… 21 November 2006 Bernard Lemoine.

BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. European.

Regulators’ response to consultation on EU legislative proposals for pharmacovigilance : common themes 2 nd International Pharmaceutical Regulatory and.

Management of Change ► The health, safety, security, environmental, technical and other impacts of temporary and permanent changes are formally assessed,

The New Drug Development Process (www. fda. gov/cder/handbook/develop

Understanding Clinical Trials – Part 2 Georgianne Arnold, MD Professor of Pediatrics University of Pittsburgh Medical Center Pittsburgh Children’s Hospital.

European Patients’ Academy on Therapeutic Innovation Marketing authorisation.

European Patients’ Academy on Therapeutic Innovation Principles of New Trial Designs.

European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Public hearings.

European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.

European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.

European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.

European Patients’ Academy on Therapeutic Innovation The Purpose and Fundamentals of Statistics in Clinical Trials.

Process mapping of registration to reimbursement for new pharmaceuticals in UK.

European Patients’ Academy on Therapeutic Innovation Special Populations.

Pharmacovigilance Convention Centre, Symbiosis Lavale Campus, Pune.

An agency of the European Union Agnes Saint Raymond, Human Medicines Special Areas Human Medicines Development and Evaluation Unit How effective is the.

European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Post-Authorisation Efficacy Studies (PAES)

European Patients’ Academy on Therapeutic Innovation Blinding in clinical trials.

European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Periodic Safety Update Reports (PSURs)

TAIEX Workshop on the Implementation of EU Pharmacovigilance Legislation - BELGRADE CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser.

Compassionate use programs and the European regulatory system Filip Josephson M.D., Ph.D. Clinical Assessor.

TAIEX Workshop on the Implementation of EU Pharmacovigilance Legislation - BELGRADE CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser.

EUPATI Training Course Patient Experts in Medicines Research & Development The project is receiving support from the Innovative Medicines Initiative Joint.

Pharmacovigilance Risk Assessment Committee (PRAC): Nye tider – nye opgaver Doris I. Stenver Overlæge, medlem af PRAC.

European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.

A capacity building programme for patient representatives

Principles of Risk Management

Efficacy and Safety of Medicines

Patient Focused Drug Development An FDA Perspective

Presented by Insert Name

Regulation EU 536/2014 on clinical trials

Risk Communication in Medicines

REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.

Pharmacovigilance in clinical trials

UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.

Union referral procedures

Helen Lee, European Commission

UKMi Observatory Observatory of recent safe medication practice research, reports, and publications Presented by Job title address.

Phase 2 to phase 3 clinical trial transitions: Reasons for success and failure in immunologic diseases Dhavalkumar D. Patel, MD, PhD, Christian Antoni,

Aspects of pharmacovigilance: Development Safety Update Report (DSUR)

Process mapping of registration to reimbursement for new pharmaceuticals in UK Description: A systematic methodology was developed in order to create the.

Presentation transcript:

European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Post-Authorisation Safety Studies (PASS)

European Patients’ Academy on Therapeutic Innovation  A PASS is a study carried out after a medicinal product has been authorised, in order to obtain further information on a medicinal product’s safety or to measure the effectiveness of risk-management measures  The purpose of the PASS is to evaluate the safety and benefit-risk profile of a medicinal product and to support regulatory decision-making  The protocols and results of PASSs are assessed by the Pharmacovigilance Risk Assessment Committee (PRAC) 2 What is a Post-Authorisation Safety Study (PASS)?

European Patients’ Academy on Therapeutic Innovation  A PASS aims to  Identify, characterise, or quantify a safety hazard;  Confirm the safety profile of a medicine; or,  Measure the effectiveness of risk-management measures.  PASSs can either be clinical trials or non-interventional studies. 3 Scope of a PASS

European Patients’ Academy on Therapeutic Innovation  European Medicines Agency (2015). Post-authorisation safety studies (PASS). Retrieved 29 September, 2015 from gulation/document_listing/document_listing_ jsp& mid=WC0b01ac058066e979 gulation/document_listing/document_listing_ jsp& mid=WC0b01ac058066e979 4 Further reading